|
1
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sheth KR and Clary BM: Management of
hepatic metastases from colorectal cancer. Clin Colon Rectal Surg.
18:215–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aoyagi T, Terracina KP, Raza A and Takabe
K: Current treatment options for colon cancer peritoneal
carcinomatosis. World J Gastroenterol. 20:12493–12500. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colon Cancer Laparoscopic or Open
Resection Study Group. Buunen M, Veldkamp R, Hop WC, Kuhry E,
Jeekel J, Haglind E, Påhlman L, Cuesta MA, Msika S, et al: Survival
after laparoscopic surgery versus open surgery for colon cancer:
Long-term outcome of a randomised clinical trial. Lancet Oncol.
10:44–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diaz LA Jr, Williams RT, Wu J, Kinde I,
Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al:
The molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:537–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nikaido H: Prevention of drug access to
bacterial targets: Permeability barriers and active efflux.
Science. 264:382–388. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ozben T: Mechanisms and strategies to
overcome multiple drug resistance in cancer. FEBS Lett.
580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghannoum MA and Rice LB: Antifungal
agents: Mode of action, mechanisms of resistance, and correlation
of these mechanisms with bacterial resistance. Clin Microbiol Rev.
12:501–517. 1999.PubMed/NCBI
|
|
12
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim AY, Kwak JH, Je NK, Lee YH and Jung
YS: Epithelial-mesenchymal transition is associated with acquired
resistance to 5-fluorocuracil in HT-29 colon cancer cells. Toxicol
Res. 31:151–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosanò L, Cianfrocca R, Spinella F, Di
Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG and Bagnato
A: Acquisition of chemoresistance and EMT phenotype is linked with
activation of the endothelin A receptor pathway in ovarian
carcinoma cells. Clin Cancer Res. 17:2350–2360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Creighton CJ, Li X, Landis M, Dixon JM,
Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A,
Herschkowitz JI, et al: Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating features.
Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hiscox S, Jiang WG, Obermeier K, Taylor K,
Morgan L, Burmi R, Barrow D and Nicholson RI: Tamoxifen resistance
in MCF7 cells promotes EMT-like behaviour and involves modulation
of beta-catenin phosphorylation. Int J Cancer. 118:290–301. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones VS, Huang RY, Chen LP, Chen ZS, Fu L
and Huang RP: Cytokines in cancer drug resistance: Cues to new
therapeutic strategies. Biochim Biophys Acta. 1865:255–265.
2016.PubMed/NCBI
|
|
19
|
Sui H, Zhu L, Deng W and Li Q:
Epithelial-mesenchymal transition and drug resistance: Role,
molecular mechanisms, and therapeutic strategies. Oncol Res Treat.
37:584–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bromann PA, Korkaya H and Courtneidge SA:
The interplay between Src family kinases and receptor tyrosine
kinases. Oncogene. 23:7957–7968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.PubMed/NCBI
|
|
22
|
Alfarouk KO, Stock CM, Taylor S, Walsh M,
Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO,
Harguindey S, et al: Resistance to cancer chemotherapy: Failure in
drug response from ADME to P-gp. Cancer Cell Int. 15:712015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu C, Krishnan J and Xu XY: Intrinsic and
induced drug resistance mechanisms: In silico investigations at the
cellular and tissue scales. Integr Biol (Camb). 7:1044–1060. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Imming P, Sinning C and Meyer A: Drugs,
their targets and the nature and number of drug targets. Nat Rev
Drug Discov. 5:821–834. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trédan O, Galmarini CM, Patel K and
Tannock IF: Drug resistance and the solid tumor microenvironment. J
Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jang M, Kim SS and Lee J: Cancer cell
metabolism: Implications for therapeutic targets. Exp Mol Med.
45:e452013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McDermott M, Eustace AJ, Busschots S,
Breen L, Crown J, Clynes M, O'Donovan N and Stordal B: In vitro
development of chemotherapy and targeted therapy drug-resistant
cancer cell lines: A practical guide with case studies. Front
Oncol. 4:402014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma X and Yu H: Global burden of cancer.
Yale J Biol Med. 79:85–94. 2006.PubMed/NCBI
|
|
31
|
Tartari F, Santoni M, Pistelli M and
Berardi R: Healthcare cost of HER2-positive and negative breast
tumors in the United States (2012–2035). Cancer treatment reviews.
60:12–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giantonio BJ, Catalano PJ, Meropol NJ,
O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III:
Eastern Cooperative Oncology Group Study E3200: Bevacizumab in
combination with oxaliplatin, fluorouracil, and leucovorin
(FOLFOX4) for previously treated metastatic colorectal cancer:
Results from the Eastern Cooperative Oncology Group Study E3200. J
Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sonowal H, Pal PB, Wen JJ, Awasthi S,
Ramana KV and Srivastava SK: Aldose reductase inhibitor increases
doxorubicin-sensitivity of colon cancer cells and decreases
cardiotoxicity. Sci Rep. 7:31822017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martino A, San KK, Daniel N and Ezekiel U:
Chemoresistance-induced epithelial-mesenchymal transition of a
colorectal cancer cell line. FASEB J. 29 Suppl 1:S721.172015.
|
|
35
|
Sen B and Johnson FM: Regulation of SRC
family kinases in human cancers. J Signal Transduct.
2011:8658192011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bromann PA, Korkaya H and Courtneidge SA:
The interplay between Src family kinases and receptor tyrosine
kinases. Oncogene. 23:7957–7968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Furcht CM, Buonato JM and Lazzara MJ:
EGFR-activated Src family kinases maintain GAB1-SHP2 complexes
distal from EGFR. Sci Signal. 8:ra462015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pengetnze Y, Steed M, Roby KF, Terranova
PF and Taylor CC: Src tyrosine kinase promotes survival and
resistance to chemotherapeutics in a mouse ovarian cancer cell
line. Biochem Biophys Res Commun. 309:377–383. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen T, Pengetnze Y and Taylor CC: Src
inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells
by caspase-9-independent activation of caspase-3. Mol Cancer Ther.
4:217–224. 2005.PubMed/NCBI
|
